Cobra Biologics has developed a cell line for Alligator Bioscience, a Swedish biotechnology company, expressing monoclonal antibodies for a Phase I clinical trail that began in April 2015.

Development of the cell line expressing the antibodies for CD40 Agonistic Immuno-Oncology ADC-1013 was performed by Cobra using the maxXpress platform used Ubiquitous Chromatin Opening Element (UCOE) technology. Combined with Cobra's cell-line development team and the Ambr robotic system, the platform enables rapid and high-yielding production of correctly folded and glycosylated recombinant proteins, complimented by Cobra's in-house cell based potency assays and high resolution mass spectrometry analytical capability. The maxXpress service can assess up to nine constructs at a time and can generate purified mixed clonal pool material in 10 weeks.

The study, led by Alligator Bioscience, will determine the safety, pharmacokinetics and pharmacodynamics of intratumourally administered ADC-1013, enrolling up to 40 patients during the dose escalation and expansion phases at five centres in the United Kingdom, Denmark, and Sweden.

Source: Cobra Biologics